Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT06796907 | A Study of Mocertatug Rezetecan in Combination With Anti-cancer Therapies for Advanced Solid Tumors | PHASE1 | RECRUITING | 305 | — | — | Mar 4, 2025 | Oct 10, 2028 | May 22, 2026 | 78 | United States, Argentina +21 |
ORR is defined as the percentage of participants with a best overall confirmed (BOR) of Partial Response (PR) or better per Response Evaluation Criteria in Solid Tumors (RECIST 1.1)
| Arm | Type | Description |
|---|---|---|
| Module 1 (Mo-Rez +Dostarlimab) Endometrial Cancer | EXPERIMENTAL | - |
| Module 2 (Mo-Rez +/-Bevacizumab) Ovarian Cancer | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Mo-Rez | DRUG | Mo-Rez will be administered intravenously (IV). |
| Dostarlimab | DRUG | Dostarlimab will be administered IV. |
| Bevacizumab | DRUG | Bevacizumab will be administered IV. |
Inclusion Criteria: * Participants must be 18 years of age inclusive or older, at the time of signing the informed consent, or the legal age of consent in the jurisdiction in which the study is taking place. * Participant capable of giving signed informed consent including compliance with the requi...